ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - azithromycin - אבקה להכנת תרחיף - azithromycin 200 mg / 5 ml - azithromycin - azithromycin - for infections caused by susceptible organisms :in lower respiratory tract infections including bronchitis and pneumonia, in skin and soft tissue infections, in otitis media and in upper respiratory tract infections including sinusitis and pharyngitis tonsillitis. azithromycin teva is also indicated in the treatment of uncomplicated genital infections due to chlamydia trachomatis.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - azithromycin - אבקה להכנת תרחיף - azithromycin 200 mg / 5 ml - azithromycin - azithromycin - for infections caused by susceptible organisms : in lower respiratory tract infections including bronchitis and pneumonia, in skin and soft tissue infections, in otitis media and in upper respiratory tract infections including sinusitis and pharyngitis tonsillitis. azithromycin teva is also indicated in the treatment of uncomplicated genital infections due to chlamydia trachomatis.

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - valaciclovir hydrochloride (as dihydrate) 500 mg - film coated tablets - valaciclovir - valaciclovir teva is indicated for the treatment of herpes zoster (shingles) in immunocompetent adults . valaciclovir teva accelerates the resolution of pain, it reduces the duration, and the proportion of patients with zoster-associated pain, which includes acute and post-herpetic neuralgia. the efficacy of valaciclovir teva in immunocompromised patients has not been established. - valaciclovir teva is indicated for the treatment of the initial and recurrent genital herpes due to herpes simplex infection. - valaciclovir is indicated for the prevention (suppression) of recurrent herpes simplex infections (herpes genitalis). - prophylaxis of cytomegalovirus infection and disease, following organ transplantation. - for the treatment of cold sores (herpes labialis).

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - acetylsalicylic acid - טבליות עם ציפוי אנטרי - acetylsalicylic acid 100 mg - acetylsalicylic acid - acetylsalicylic acid - the primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - acetylsalicylic acid - טבליות עם ציפוי אנטרי - acetylsalicylic acid 100 mg - acetylsalicylic acid - acetylsalicylic acid - the primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - acetylsalicylic acid - טבליות עם ציפוי אנטרי - acetylsalicylic acid 100 mg - acetylsalicylic acid

ישראל - עברית - Ministry of Health

teva medical ltd. - migada - אחות - see attached document : us fda 510(k) k051669 approved indications for use

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - etodolac - טבליה - etodolac 600 mg - etodolac - etodolac - for the management of signs and symptoms of osteoarthritis and rehumatoid arthritis.

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - rosuvastatin as calcium 5 mg - tablets - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - rosuvastatin as calcium 10 mg - tablets - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.